Spotlight On... Sensus squeaks out with $11M IPO for low-energy x-ray treatment; University of Missouri studies show monitoring walking speed and heart health can maintain older adult health; and more...

Sensus Healthcare ($SRTSU) raised $11 million by selling 2 million units at $5.50. That was after the company had reduced its proposed price of $6.25. This is the third med tech IPO in the U.S. this week; Clearside Biomedical ($CLSD) similarly had to reduce its price ahead of the IPO but traded up in its first day. Sensus was also gaining ground in early trading--up 7% in early trading to $5.90. The company offers superficial radiation treatment devices for non-melanoma skin cancer and keloids with installations in more than 220 locations. More

> Waltham, MA-based wearables and point-of-care test maker Neurometrix ($NURO) announced it has entered into a definitive securities purchase agreement totaling $21.3 million. Release

> University of Missouri researchers reported data from studies that demonstrate how monitoring walking speed using radar and heart health using bed sensors can help maintain older adults' health. Release

> Provision Asia and Shenzhen Hairong International Medical Development Co. formed a joint venture, Provision Asia, which will develop cancer centers and proton therapy centers in China. It will also distribute Proton Therapy Systems developed by Provision Healthcare in China. Release